Atara Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Commercialization revenue | $7,886 | $— |
| License and collaboration revenue | 687 | 63,573 |
| Total revenue | 8,573 | 63,573 |
| Costs and operating expenses: | ||
| Cost of commercialization revenue | 8,886 | — |
| Research and development expenses | 224,785 | 272,533 |
| General and administrative expenses | 50,908 | 71,553 |
| Total costs and operating expenses | 284,579 | 344,086 |
| Loss from operations | (276,006) | (280,513) |
| Other income (expense), net: | ||
| Interest income | 5,426 | 3,059 |
| Interest expense | (5,285) | (373) |
| Gain on sale of ATOM Facility (See Note 7) | — | 50,237 |
| Other income (expense), net: | (246) | (700) |
| Total other income (expense), net | (105) | 52,223 |
| Loss before provision for income taxes | (276,111) | (228,290) |
| Provision for income taxes | 15 | 12 |
| Net loss | $(276,126) | $(228,302) |
| Other comprehensive gain (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | 1,863 | (1,699) |
| Comprehensive loss | $(274,263) | $(230,001) |
| Basic and diluted net loss per common share | $(2.61) | $(2.24) |
| Basic and diluted weighted-average shares outstanding | 105,912 | 101,990 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.